Revenue growth of leading 25 domestic drug firms is expected to moderate to 8-10 per cent in the next fiscal year, rating ...
Import Alert 99-48, Detention without Physical Examination of Foods Due to Chemical Contamination, includes a broad range of synthetic contaminants, including benzene, dioxins, polychlorinated ...
The U.S. Food and Drug Administration has extended its review of Applied Therapeutics' experimental drug to treat ...
(RTTNews) - Amneal Pharmaceuticals Inc. (AMRX) said it has received Abbreviated New Drug Application approval from the U.S. Food and Drug Administration for ciprofloxacin and dexamethasone otic ...
Amneal Pharmaceuticals said the Food and Drug Administration has approved its abbreviated new drug application for ciprofloxacin and dexamethasone otic suspension, a combination used to treat ...
(RTTNews) - Amneal Pharmaceuticals Inc. (AMRX) said it has received Abbreviated New Drug Application approval from the U.S. Food and Drug Administration for ciprofloxacin and dexamethasone otic ...
Prevailing regulations state that only “on-label” claims may be used by manufacturers in pharma advertising. A draft guidance released this week by the Food and Drug Administration, provides an ...
a once-daily pill developed by Madrigal Pharmaceuticals. The FDA decision Thursday is for adults with noncirrhotic non-alcoholic steatohepatitis, or NASH. The approval specifically covers those ...
Stock Market News: Domestic equity benchmark indices, the Sensex and Nifty 50, had a sluggish start to the Tuesday session as investors booked profits on the back of weekly gains and there were no ...
Last year, J&J filed patent infringement lawsuits against Sun Pharma, Alembic Pharma, Apotex and MSN Laboratories, all of which have filed FDA applications for their generic versions of Opsumit.
Nearly five years after an FDA approval for Soliris in neuromyelitis ... nephritis and immunoglobulin A nephropathy. The British pharma suffered a setback recently as it canned a phase 2 trial ...
Innocan is now initiating the following essential development steps that are expected to move LPT-CBD to a pharmaceutical-grade product that must be qualified by the FDA for both the clinical and ...